Atrium Therapeutics, Inc. (RNA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-04-22

Atrium Therapeutics, Inc. (RNA) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-04-22. 2 Form 8-K material event filings were reported by RNA in the last 90 days. InsiderAlpha tracks every RNA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Atrium Therapeutics, Inc. (RNA)

SEC CIK	0002093101

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-04-22

Recent RNA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-04-20	Kenney Stephanie	See Remarks	A — Grant or award	30.0K	$0.00	—	SEC
2026-04-20	Hughes Steven George	Chief Medical Officer	A — Grant or award	30.0K	$0.00	—	SEC
2026-04-20	Winslow Brendan R.	Chief Financial Officer	A — Grant or award	30.0K	$0.00	—	SEC
2026-04-20	Gallagher Kathleen P.	See Remarks	A — Grant or award	102.5K	$0.00	—	SEC
2026-04-20	Hoyos Rocio Martin	Chief Strategy Officer	A — Grant or award	30.0K	$0.00	—	SEC
2026-04-20	Younis Husam	Chief Scientific Officer	A — Grant or award	30.0K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Atrium Therapeutics, Inc. (RNA). Updated in real time as new filings are submitted to the SEC.

Most-Active RNA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Hughes Steven George	2	—
Gallagher Kathleen P.	2	—
Kenney Stephanie	2	—
Winslow Brendan R.	2	—
Hoyos Rocio Martin	2	—

Recent RNA Form 8-K Material Events

2026-07-14 — Item 8.01, 9.01 [SEC]
2026-05-14 — Item 2.02, 9.01 [SEC]

Recent Insider Filings

2026-04-22 — Kenney Stephanie (See Remarks)
2026-04-22 — Hughes Steven George (Chief Medical Officer)
2026-04-22 — Winslow Brendan R. (Chief Financial Officer)
2026-04-22 — Gallagher Kathleen P. (See Remarks)
2026-04-22 — Hoyos Rocio Martin (Chief Strategy Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RNA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

RNA Insider Trading — FAQ

What is the latest insider trade for RNA?: Atrium Therapeutics, Inc. (RNA) had 6 insider filings in the last 90 days, with the most recent on 2026-04-22. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying RNA stock?: 0 insider purchases of RNA were filed in the last 90 days.
How many insiders are selling RNA stock?: 0 insider sales of RNA were filed in the last 90 days.
Where can I see RNA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every RNA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live RNA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.